Tiago Fauth
Stock Analyst at Wells Fargo
(2.35)
# 2,394
Out of 5,182 analysts
144
Total ratings
42.2%
Success rate
-0.22%
Average return
Main Sectors:
Stocks Rated by Tiago Fauth
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Maintains: Overweight | $171 → $217 | $140.01 | +54.99% | 9 | Oct 31, 2025 | |
| WVE Wave Life Sciences | Maintains: Overweight | $21 → $18 | $7.47 | +140.96% | 4 | Sep 4, 2025 | |
| UTHR United Therapeutics | Maintains: Equal-Weight | $295 → $414 | $581.22 | -28.77% | 7 | Sep 3, 2025 | |
| MNKD MannKind | Maintains: Overweight | $9 → $10 | $2.81 | +255.87% | 2 | Sep 3, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $79 → $73 | $65.49 | +11.47% | 5 | Aug 20, 2025 | |
| LQDA Liquidia | Maintains: Overweight | $25 → $31 | $38.48 | -19.44% | 3 | Aug 13, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $333 → $395 | $297.93 | +32.58% | 7 | Aug 1, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $88 → $65 | $24.82 | +161.89% | 8 | Jul 10, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $67 → $76 | $68.99 | +10.16% | 1 | Jun 30, 2025 | |
| SVRA Savara | Maintains: Overweight | $8 → $7 | $5.30 | +32.08% | 2 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $112 → $101 | $29.65 | +240.64% | 4 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $3 | $1.19 | +152.10% | 2 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $26 | $11.71 | +122.03% | 6 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $75 | $67.64 | +10.88% | 1 | Aug 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $89 | $228.71 | -61.09% | 16 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $51 | $14.06 | +262.73% | 3 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $120 | $55.46 | +116.37% | 7 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $4 | $27.85 | -85.64% | 4 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $5.62 | +149.11% | 4 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $300 | $59.37 | +405.31% | 5 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $26 | $9.25 | +181.08% | 5 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $28 | $4.59 | +510.02% | 7 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $81 | $40.97 | +97.71% | 11 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $400 | $4.70 | +8,410.64% | 5 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $1.76 | +695.45% | 2 | Mar 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $38 → $34 | $1.88 | +1,708.51% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $29 | $44.17 | -34.34% | 1 | Jan 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $1.41 | +821.99% | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $13 | $3.00 | +333.33% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $2.5 → $2 | $2.13 | -6.10% | 4 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $297 → $340 | $811.09 | -58.08% | 3 | Dec 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $265 → $259 | $323.85 | -20.02% | 1 | Apr 28, 2021 |
Insmed
Oct 31, 2025
Maintains: Overweight
Price Target: $171 → $217
Current: $140.01
Upside: +54.99%
Wave Life Sciences
Sep 4, 2025
Maintains: Overweight
Price Target: $21 → $18
Current: $7.47
Upside: +140.96%
United Therapeutics
Sep 3, 2025
Maintains: Equal-Weight
Price Target: $295 → $414
Current: $581.22
Upside: -28.77%
MannKind
Sep 3, 2025
Maintains: Overweight
Price Target: $9 → $10
Current: $2.81
Upside: +255.87%
PTC Therapeutics
Aug 20, 2025
Maintains: Overweight
Price Target: $79 → $73
Current: $65.49
Upside: +11.47%
Liquidia
Aug 13, 2025
Maintains: Overweight
Price Target: $25 → $31
Current: $38.48
Upside: -19.44%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Equal-Weight
Price Target: $333 → $395
Current: $297.93
Upside: +32.58%
Ultragenyx Pharmaceutical
Jul 10, 2025
Maintains: Overweight
Price Target: $88 → $65
Current: $24.82
Upside: +161.89%
BridgeBio Pharma
Jun 30, 2025
Maintains: Overweight
Price Target: $67 → $76
Current: $68.99
Upside: +10.16%
Savara
May 28, 2025
Maintains: Overweight
Price Target: $8 → $7
Current: $5.30
Upside: +32.08%
Mar 21, 2025
Maintains: Overweight
Price Target: $112 → $101
Current: $29.65
Upside: +240.64%
Mar 4, 2025
Maintains: Equal-Weight
Price Target: $4 → $3
Current: $1.19
Upside: +152.10%
Feb 27, 2025
Maintains: Overweight
Price Target: $28 → $26
Current: $11.71
Upside: +122.03%
Aug 22, 2024
Initiates: Overweight
Price Target: $75
Current: $67.64
Upside: +10.88%
Jun 14, 2023
Assumes: Neutral
Price Target: $89
Current: $228.71
Upside: -61.09%
Jun 14, 2023
Assumes: Outperform
Price Target: $51
Current: $14.06
Upside: +262.73%
Jun 14, 2023
Assumes: Outperform
Price Target: $120
Current: $55.46
Upside: +116.37%
May 23, 2023
Reiterates: Underperform
Price Target: $4
Current: $27.85
Upside: -85.64%
May 16, 2023
Reiterates: Outperform
Price Target: $14
Current: $5.62
Upside: +149.11%
May 16, 2023
Reiterates: Outperform
Price Target: $300
Current: $59.37
Upside: +405.31%
May 11, 2023
Reiterates: Outperform
Price Target: $26
Current: $9.25
Upside: +181.08%
May 5, 2023
Maintains: Outperform
Price Target: $34 → $28
Current: $4.59
Upside: +510.02%
May 5, 2023
Maintains: Neutral
Price Target: $70 → $81
Current: $40.97
Upside: +97.71%
Mar 24, 2023
Reiterates: Neutral
Price Target: $400
Current: $4.70
Upside: +8,410.64%
Mar 23, 2023
Reiterates: Outperform
Price Target: $14
Current: $1.76
Upside: +695.45%
Mar 10, 2023
Maintains: Outperform
Price Target: $38 → $34
Current: $1.88
Upside: +1,708.51%
Jan 26, 2023
Initiates: Outperform
Price Target: $29
Current: $44.17
Upside: -34.34%
Dec 16, 2022
Initiates: Outperform
Price Target: $13
Current: $1.41
Upside: +821.99%
Nov 18, 2022
Downgrades: Neutral
Price Target: $25 → $13
Current: $3.00
Upside: +333.33%
May 13, 2022
Maintains: Underperform
Price Target: $2.5 → $2
Current: $2.13
Upside: -6.10%
Dec 20, 2021
Maintains: Neutral
Price Target: $297 → $340
Current: $811.09
Upside: -58.08%
Apr 28, 2021
Maintains: Outperform
Price Target: $265 → $259
Current: $323.85
Upside: -20.02%